For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 42,633 | |||
| General and administrative | 21,916 | |||
| Total operating expenses | 64,549 | |||
| Income (loss) from operations | -64,549 | |||
| Interest and investment income (expense) | 6,380 | |||
| Other income (expense) | 730 | |||
| Other income (expense), net | 7,110 | |||
| Net income (loss) | -57,439 | |||
| Net unrealized gain (loss) on marketable debt securities | 88 | |||
| Other comprehensive income (loss) | 88 | |||
| Comprehensive income (loss) | -57,351 | |||
| Basic EPS | -1.34 | |||
| Diluted EPS | -1.34 | |||
| Basic Average Shares | 42,836,129 | |||
| Diluted Average Shares | 42,836,129 | |||
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)